2996841-28-0
Chemical Structure
N-19004
- CAS No.: 2996841-28-0
- Formula:C29H38N8O2S
- Molecular Weight:562.73
InChIKey: OFOQBHQUIUUNGN-UHFFFAOYSA-N
SMILES: CC(C)(C1=CC(NC(CC/N=C(N)/N)=O)=C(C(NC(CC/N=C(N)/N)=O)=C1)SCC2=CC=C3C=CC=CC3=C2)C
Biological Activity: N-19004 is a FPR1 antagonist. N-19004 shows broad-spectrum antibacterial effects against a variety of pathogens. N-19004 exhibits significant retinal protective effects in the rd10 mouse model of retinitis pigmentosa (RP). N-19004 can attenuate retinal dysfunction, mitigate rod and cone degeneration, and reduce immune cell activation, gliosis, inflammation, oxidative stress, and apoptosis. N-19004 can reduce the size of laser-induced choroidal lesions and promote edema absorption through dual anti-inflammatory and anti-angiogenic effects. N-19004 can be used for the research of retinal degenerative diseases such as retinitis pigmentosa[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
N-19004 | N-19004 is a FPR1 antagonist. N-19004 shows broad-spectrum antibacterial effects against a variety of pathogens. N-19004 exhibits significant retinal protective effects in the rd10 mouse model of retinitis pigmentosa (RP). N-19004 can attenuate retinal dysfunction, mitigate rod and cone degeneration, and reduce immune cell activation, gliosis, inflammation, oxidative stress, and apoptosis. N-19004 can reduce the size of laser-induced choroidal lesions and promote edema absorption through dual anti-inflammatory and anti-angiogenic effects. N-19004 can be used for the research of retinal degenerative diseases such as retinitis pigmentosa. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Amato R, et al. Inhibiting The uPA/uPAR Pathway Affords Photoreceptor Resilience and Preserves Retinal Function in a Mouse Model of Retinitis Pigmentosa. Invest Ophthalmol Vis Sci. 2025 Aug 1;66(11):29. [Content Brief]
- [2]. De Fenza M, et al. Dual-action thioarylamide-based small molecules to target drug-resistant bacteria and chronic inflammation. iScience. 2025 Oct 3;28(11):113674. [Content Brief]
Keywords
